Purpose
The purpose of the Fellowship Program is to build, in collaboration with industry, Canadian capacity and expertise in the area of oncology and to promote excellence in research through training awards. The goals of the program are to provide an opportunity for individuals who have completed their Medical Oncology training in Canada to have additional clinical and/or fundamental research experience.
Past Recipients
2023
Dr. Kevin (Xin) WANG
COMPREHENSIVE MOLECULAR CHARACTERIZATION OF THE TUMOUR, HOST, AND GUT MICROBIOME INTERACTION IN ADVANCE HEPATOCELLULAR CARCINOMA
2022
Dr. Carly BARRON
CROSS TUMOUR-COMPARISON OF THE TUMOR IMMUNE-MICROENVIRONMENT, PERIPHERAL IMMUNE SIGNATURES AND RESPONSE TO IMMUNOTHERAPY AS A NOVEL CONCEPTUAL MODEL IN AERODIGESTIVE TUMORS
2021
Dr. Lucy MA
ENHANCING MEDICATION SAFETY IN AMBULATORY CANCER CARE
2020
Dr. Erica TSANG
CIRCULATING TUMOR DNA AND METABOLIC IMAGING IN RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA (DIRECT-PDAC)
2019
Dr. Lawson ENG
ACUTE CARE USE AND OUTCOMES OF IMMUNE-RELATED ADVERSEEVENTS (IRAES) DURING IMMUNOTHERAPY
2018
Dr. Michael RAPHAEL
VOLUME-OUTCOME ASSOCIATION FOR THE SYSTEMIC TREATMENT OF CANCER: A POPULATION BASED STUDY
2017
Dr. Doreen EZEIFE
ESTABLISHING A LEVEL PLAYING FIELD: DEVELOPMENT OF A VALUE ASSESSMENT FRAMEWORK FOR ONCOLOGY DRUGS
2016
Dr. Jonathan LOREE
IMPACT OF INTRATUMOR HETEROGENEITY AND LOW FREQUENCY RAS MUTATIONS ON CLINICAL OUTCOME IN COLORECTAL CANCER
2015
Dr. Katarzyna JERZAK
THYROID HORMONE RECEPTORS IN BREAST CANCER- PROGNOSTIC, PREDICTIVE AND THERAPEUTIC IMPLICATIONS
Dr. Sunil PARIMI
GENOMIC PROFILING OF CIRCULATING TUMOR DNA (CTDNA) AS A PREDICTIVE BIOMARKER FOR PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER
2014
Dr. Adrian G SACHER
TRANSLATING TARGETED NEXT-GENERATION SEQUENCING INTO A CLINICAL TOOL FOR PERSONALIZED MANAGEMENT OF SQUAMOUS CELL LUNG CANCER
2013
Dr. Nimira ALIMOHAMED
BONE TARGETED THERAPY FOR PROSTATE CANCER IN CANADA: PRACTICE PATTERNS AND IMPACT ON OUTCOMES
Dr. Christina KIM
PREDICTIVE AND PROGNOSTIC IMPACTS OF QUALITY OF LIFE MEASUREMENTS AND BIOMARKER DISCOVERY IN CHEMOTHERAPY TREATED ADVANCED PANCREATIC CANCER PATIENTS IN NORTHERN ALBERTA
Dr. Ravi RAMJEESINGH
ASSOCIATION BETWEEN TIMES TO ADMINISTRATION OF ADJUVANT CHEMOTHERAPY AND OUTCOMES IN EARLY BREAST CANCER: ANALYSIS OF ADJUVANT STUDIES CONDUCTED BY NCIC CLINICAL TRIALS GROUP
2012
Dr. David DAWE
ASSESSMENT OF HEALTH CARE PATTERNS FOR ELDERLY LUNG CANCER PATIENTS IN SOUTHERN ONTARIO
Dr. Tina HSU
PHYSICAL, EMOTIONAL AND SOCIAL STRESSORS AND THEIR IMPACT ON QUALITY OF LIFE OF CAREGIVERS OF ELDERLY PATIENTS WITH CANCER
Dr. Demetrios SIMOS
A PHASE 2 CLINICAL TRIAL EXPLORING THE CLINICAL AND CORRELATIVE EFFECTS OF COMBINING DOXYCYCLINE WITH STANDARD BISPHOSPHONATE THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER (THE ACHILLES STUDY)
2011
Dr. Maria HO
EXPECTATIONS OF CARE FOR YOUNG ADULT SURVIVORS OF CHILDHOOD CANCERS
Dr. Solmaz SAHEBJAM
EVALUATING THE ANTI-TUMOR ACTIVITY OF A DUAL IGF-1R AND IR INHIBITOR (OSI-906) IN GENOMICALLY CHARACTERIZED HUMAN BREAST CANCER (BC) XENOGRAFT MODEL
2010
Dr. Nicole CHAU
UNDERSTANDING MECHANISMS OF RESISTANCE TO EGRF INHIBITORS IN HEAD AND NECK CANCER
Dr. David CESCON
MOLECULAR PATHOGENESIS OF BRCA1-ASSOCIATED AND TRIPLE-NEGATIVE BREAST CANCER: MECHANISM OF TISSUE SPECIFICITY AND IDENTIFICATION AND CHARACTERIZATION OF COOPERATING TUMORIGENIC PATHWAYS
Dr. Vincent TAM
A PHASE II TRIAL COMPARING LOW DOSE METRONOMIC CYCLOPHOSPHAMIDE AND CEDIRANIB TO CYCLOPHOSPHAMIDE AND PLACEBO AS MAINTENANCE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
2009
Andrea MOLCKOVSKY
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY OF BIOFLUIDS: IDENTIFICATION OF ONCOLOGIC BIOMARKERS
Mateya E TRINKAUS
CLINICAL AND TRANSLATIONAL STUDIES OF HYPOXIA IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Michael VICKERS
PRECLINICAL/CLINICAL EVALUATION OF A CDK4/6 INHIBITOR + 5-FU IN COLON CANCER
2008
Dr. Phil BEDARD
DETERMINANTS OF GENOMIC RISK IN EARLY-STAGE BREAST CANCER
Dr. Janine DAVIES
PHASE IB STUDY OF SORAFENIB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA AND CHILD’S B CIRRHOSIS
Dr. Leora HORN
A PHASE II TRIAL OF CELECOXIB PLUS CHEMOTHERAPY [DOCETAXEL] OR [PEMETREXED] IN PATIENTS WITH PREVIOUSLY TREATED, ‘COX DEPENDENT’ RECURRENT NON-SMALL CELL LUNG CANCER
Dr. Winson CHEUNG
DISCORDANCES BETWEEN PATIENT AND PHYSICIAN EXPECTATIONS FOR CANCER SURVIVORSHIP CARE
2007
Dr. Orit FREEDMAN
THE DEVELOPMENT OF A PROSPECTIVE, VALIDATED RISK INDEX FOR SKELETAL RELATED EVENTS IN BREAST CANCER PATIENTS WITH BONE METATSTASES
Dr. Howard LIM
A PHASE II STUDY LINE SUNITINIB IN PREVIOUSLY TREATED PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METATSTATIC PANCREATIC CANCER
Dr. Daniel HENG
A PHASE II STUDY OF SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (RCC) REFRACTORY TO PRIOR SUNITINIB OR BEVACIZUMAB THERAPY
2006
Dr. Christine SIMMONS
CHANGES IN BREAST TUMOR RECEPTOR STATUS WITH TIME-DOES PERFORMING A CONFIRMATORY BIOPSY AT THE TIME OF METASTIC RECURRENCE ALTER PATIENT MANAGEMENT?
Dr. Heather MCARTHUR
AN OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY PHARMACOKINETICS AND ACTIVITY OF LAPATINIB IN COMBINATION WITH BEVACIZUMB (AVASTIN) IN METASTATIC BREAST CANCER
Jennifer L SPRATLIN
A PHASE I STUDY OF PXD101 IN COMBINATION WITH BORTEZOMIB (PS-341) IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMA WITH TRANSLATIONAL RESEARCH COMPONENTS
| Canadian Association of Medical Oncologists | Phone: 613.415.6033 |